NASDAQ: BTAIBioxcel Therapeutics Inc Stock Ownership - Who owns Bioxcel Therapeutics?
Insider buying vs selling
Have Bioxcel Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Frank Yocca | Chief Scientific Officer | 2024-12-16 | 225 | $0.35 | $78.98Sell |
| Vimal Mehta | CEO and President | 2024-12-16 | 983 | $0.36 | $357.81Sell |
| Vimal Mehta | CEO and President | 2024-12-16 | 2,134 | $0.36 | $772.51Sell |
| Vincent Oneill | Executive Vice President Chief of Product Development and Medical Officer | 2024-12-16 | 165 | $0.35 | $58.08Sell |
| Javier Rodriguez | Chief Legal Officer Senior Vice President and Corporate Secretary | 2024-12-16 | 210 | $0.36 | $74.55Sell |
| Javier Rodriguez | Chief Legal Officer Senior Vice President and Corporate Secretary | 2024-12-16 | 220 | $0.36 | $78.54Sell |
| Richard I. Steinhart | Chief Financial Officer | 2024-12-16 | 205 | $0.36 | $73.80Sell |
| Richard I. Steinhart | Chief Financial Officer | 2024-12-16 | 372 | $0.36 | $133.18Sell |
| Frank Yocca | Chief Scientific Officer | 2024-12-16 | 205 | $0.36 | $72.77Sell |
| Matthew T. Wiley | Chief Commercial Officer | 2024-10-03 | 6,272 | $0.55 | $3.45kSell |
BTAI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when BTAI insiders and whales buy or sell their stock.
BTAI Shareholders
What type of owners hold Bioxcel Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Vimal Mehta | 120.87% | 17,594,079 | $87.62M | Insider |
| Bioxcel Holdings Inc | 120.68% | 17,566,750 | $87.48M | Insider |
| Krishnan Nandabalan | 117.43% | 17,094,500 | $85.13M | Insider |
| Vipin Agarwal | 58.77% | 8,554,945 | $42.60M | Insider |
| Rashmi Agarwal | 58.77% | 8,554,945 | $42.60M | Insider |
| Indu R. Gupta | 58.74% | 8,550,396 | $42.58M | Insider |
| Tarun K. Gupta | 58.74% | 8,550,396 | $42.58M | Insider |
| Suganthi Balasubramanian | 58.72% | 8,547,750 | $42.57M | Insider |
| Diwakar Jain | 58.72% | 8,547,300 | $42.57M | Insider |
| Anita Jain | 58.72% | 8,547,300 | $42.57M | Insider |
BTAI vs Biotech Stocks
Bioxcel Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.